What kind of company is KESIMPTA?

About KESIMPTA

KESIMPTA is a medication for the treatment of relapsing forms of multiple sclerosis (MS) that is developed and marketed by Novartis Pharmaceuticals Corporation. The active ingredient in KESIMPTA is ofatumumab, which is a monoclonal antibody that targets a specific protein on the surface of B cells.

Efficacy and Safety

KESIMPTA has been approved by the US Food and Drug Administration (FDA) as a treatment for relapsing forms of MS. In clinical trials, KESIMPTA was found to be highly effective in reducing the number of relapses experienced by patients. KESIMPTA has also been shown to slow the progression of disability in patients with RMS.

Cost Savings and Support Programs

In addition to providing a highly effective treatment option, Novartis Pharmaceuticals Corporation also offers cost savings and support programs for patients who are prescribed KESIMPTA. These programs aim to provide financial assistance for patients who may have limited or no insurance coverage for their medications.

Accessibility and Availability

KESIMPTA is available in the United States as a self-administered subcutaneous injection. Patients who are prescribed KESIMPTA can administer the medication themselves at home under the guidance of their healthcare provider.

Conclusion

KESIMPTA is a highly effective medication for the treatment of relapsing forms of MS that offers a range of cost savings and support programs to help patients access the medication they need. Developed and marketed by Novartis Pharmaceuticals Corporation, KESIMPTA represents a significant advancement in the treatment of MS and provides hope for patients living with this chronic condition.